MCID: DGS008
MIFTS: 18

Digestive System Melanoma

Categories: Rare diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Digestive System Melanoma

MalaCards integrated aliases for Digestive System Melanoma:

Name: Digestive System Melanoma 50 69
Malignant Melanoma of the Gastrointestinal Tract 50
Melanoma of the Gastrointestinal Tract 50
Primary Gastrointestinal Melanoma 50
Melanoma of the Gi Tract 50

Classifications:



Summaries for Digestive System Melanoma

NIH Rare Diseases : 50 digestive system melanoma refers to a melanoma starting in the stomach, intestines, salivary glands, mouth, esophagus, liver, pancreas, gallbladder, or rectum. melanoma is a disease in which malignant (cancer) cells form in the melanocytes. melanocytes are commonly found in the skin and are the cells that give the skin color. while it is not uncommon for melanomas to start in the skin and later spread to other parts of the body (metastasize), melanomas originating in the gastrointestinal tract are rare. the most frequently reported site is in the esophagus and anorectum. symptoms of a digestive system melanoma may be nonspecific, including blood in the stool, stomach pain, vomiting, diarrhea, weight loss and anemia (low red blood cell count). the cause of digestive system melanoma is not well understood. some researchers theorize that it may have originated from an undetected primary tumor. treatment may include surgical excision of the gastrointestinal tract involved, chemotherapy, and immunotherapy. last updated: 6/23/2016

MalaCards based summary : Digestive System Melanoma, also known as malignant melanoma of the gastrointestinal tract, is related to gastric ulcer and melanoma. The drugs Somatostatin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and colon.

Related Diseases for Digestive System Melanoma

Diseases related to Digestive System Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 gastric ulcer 9.8
2 melanoma 9.8

Symptoms & Phenotypes for Digestive System Melanoma

Drugs & Therapeutics for Digestive System Melanoma

Drugs for Digestive System Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved Phase 4,Phase 1 38916-34-6, 51110-01-1 53481605
2
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
3 Hormones Phase 4,Phase 1
4 Hormone Antagonists Phase 4,Phase 1
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1
6
Morphine Approved, Investigational Phase 3,Phase 2 57-27-2 5288826
7
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 1 33069-62-4 36314
9
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
10 Deoxyglucose Phase 3
11 Fluorodeoxyglucose F18 Phase 3
12 Radiopharmaceuticals Phase 3,Phase 1
13 Liver Extracts Phase 3,Phase 1,Phase 2,Early Phase 1
14 Anti-Infective Agents Phase 3,Phase 1,Phase 2
15 Antiviral Agents Phase 3,Phase 1,Phase 2
16 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
17 Analgesics Phase 3,Phase 2,Phase 1
18 Anesthetics Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
20 Albumin-Bound Paclitaxel Phase 3,Phase 1
21 Antimetabolites Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 1,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
25 Analgesics, Opioid Phase 3
26 Anesthetics, Local Phase 3
27 Central Nervous System Depressants Phase 3,Phase 1
28 Narcotics Phase 3
29 Cola Nutraceutical Phase 3,Phase 1,Phase 2,Early Phase 1
30
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
31
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
32
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
33
Methamphetamine Approved, Illicit Phase 2 537-46-2 10836
34
Aldesleukin Approved Phase 2,Phase 1 85898-30-2, 110942-02-4
35
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
36
Vidarabine Approved Phase 2,Phase 1 24356-66-9 32326 21704
37
Lorazepam Approved Phase 2 846-49-1 3958
38
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
39
nivolumab Approved Phase 2,Phase 1 946414-94-4
40
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
41
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
42
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
43
Coal tar Approved Phase 1, Phase 2 8007-45-2
44
Vinblastine Approved Phase 1, Phase 2 865-21-4 13342 241903
45
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
46
Trametinib Approved Phase 2 871700-17-3 11707110
47
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Dabrafenib Approved Phase 2 44462760 44516822
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 177)

id Name Status NCT ID Phase Drugs
1 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
2 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
3 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
4 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
5 Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery Recruiting NCT01318161 Phase 3 Ropivacaine + opioid epidurally;Morphine
6 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel 125 mg/m2;gemcitabine 1000 mg/m2;gemcitabine 1000 mg/m2
7 TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients Unknown status NCT01409733 Phase 1, Phase 2
8 Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Unknown status NCT00108875 Phase 1, Phase 2
9 IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma Unknown status NCT00294476 Phase 2 IVIG
10 Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors Unknown status NCT00610389 Phase 2
11 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Unknown status NCT00553683 Phase 1, Phase 2 cyclophosphamide;poly ICLC
12 Safety and Efficacy Study of DCVax-Direct in Solid Tumors Unknown status NCT01882946 Phase 1, Phase 2
13 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Completed NCT01290536 Phase 2
14 Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer Completed NCT00311272 Phase 2
15 Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver Completed NCT00041808 Phase 1, Phase 2 MTC-DOX for Injection
16 Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors Completed NCT00855452 Phase 2
17 Testing of ADI-PEG in Hepatocellular Carcinoma Completed NCT00056992 Phase 2 ADI-PEG 20
18 Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) Completed NCT00635193 Phase 1, Phase 2 M200 (Volociximab);Liposomal Doxorubicin;M200 (Volociximab);M200 (Volociximab)
19 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
20 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
21 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
22 Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer Recruiting NCT02437136 Phase 1, Phase 2 entinostat;pembrolizumab
23 Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Recruiting NCT03101566 Phase 2 Gemcitabine;Cisplatin;Ipilimumab;Nivolumab
24 Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy Recruiting NCT02307500 Phase 2 Regorafenib
25 Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Recruiting NCT02807844 Phase 1, Phase 2 MCS110;PDR001
26 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Recruiting NCT03058289 Phase 1, Phase 2 INT230-6
27 Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer Recruiting NCT02907099 Phase 2 BL-8040;Pembrolizumab
28 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Recruiting NCT02327078 Phase 1, Phase 2 Nivolumab (Phase 1);Epacadostat (Phase 1);Chemotherapy (Phase 1);Nivolumab (Phase 2);Epacadostat (Phase 2)
29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting NCT01174121 Phase 2 Aldesleukin;Cyclophosphamide;Fludarabine;Pembrolizumab
30 Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer Recruiting NCT02305186 Phase 1, Phase 2 Pembrolizumab
31 A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer Recruiting NCT02399943 Phase 2 Trametinib;Panitumumab
32 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2 Entrectinib
33 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Recruiting NCT02465060 Phase 2 Afatinib;Akt inhibitor AZD5363;Binimetinib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib;WEE1 Inhibitor AZD1775
34 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting NCT01037790 Phase 2 PD-0332991
35 Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE) Recruiting NCT02576431 Phase 2 LOXO-101
36 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
37 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Recruiting NCT02830724 Phase 1, Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
38 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Recruiting NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
39 A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Active, not recruiting NCT02452424 Phase 1, Phase 2 PLX3397
40 A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued. Active, not recruiting NCT00378482 Phase 2 CP-675,206 (Tremelimumab)
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 Survivorship Promotion In Reducing IGF-1 Trial Active, not recruiting NCT02431676 Phase 2 Metformin
43 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Not yet recruiting NCT03220009 Phase 2
44 Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer Not yet recruiting NCT03300843 Phase 2
45 Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer Not yet recruiting NCT03186326 Phase 2 FOLFOX regimen;FOLFIRI Protocol;Avelumab;Panitumumab;Cetuximab;Bevacizumab;Aflibercept
46 Epacadostat and Pembrolizumab in Patients With GIST Not yet recruiting NCT03291054 Phase 2 Pembrolizumab;Epacadostat
47 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Not yet recruiting NCT03207867 Phase 2 NIR178;PDR001
48 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib
49 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
50 MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. Terminated NCT00147550 Phase 1, Phase 2 PD-0325901

Search NIH Clinical Center for Digestive System Melanoma

Genetic Tests for Digestive System Melanoma

Anatomical Context for Digestive System Melanoma

MalaCards organs/tissues related to Digestive System Melanoma:

39
Liver, Testes, Colon, Pancreas, Skin, Salivary Gland, Breast

Publications for Digestive System Melanoma

Variations for Digestive System Melanoma

Expression for Digestive System Melanoma

Search GEO for disease gene expression data for Digestive System Melanoma.

Pathways for Digestive System Melanoma

GO Terms for Digestive System Melanoma

Sources for Digestive System Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....